Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Jochen Weber

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|February 26, 2026
Population PK/PD Modeling for Evaluation of Intertwining Effects of Drug and Disease on Thrombocytopenia in Acute LeukemiasTomás Sou, Kamel Malek, Hans-Jochen Weber
Statistics in Medicine|September 16, 2025
Towards Efficient Time-to-Event Dose-Escalation Guidance of Multi-Cycle Cancer TherapiesLukas A Widmer, Sebastian Weber, Yunnan Xu, et al.
Pharmaceutical Statistics|March 9, 2021
Estimands in hematologic oncology trialsSteven Sun, Hans-Jochen Weber, Emily Butler, et al.
Pharmaceutical Statistics|March 29, 2024
Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidanceJonathan M Siegel, Hans-Jochen Weber, Stefan Englert, et al.
Pharmaceutical Statistics|March 27, 2023
Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questionsKaspar Rufibach, Lynda Grinsted, Jiang Li, et al.
Pulmonary Pharmacology & Therapeutics|January 15, 2009
Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthmaSøren Pedersen, Renate Engelstätter, Hans-Jochen Weber, et al.
Pharmaceutical Statistics|October 3, 2023
Duration of and time to response in oncology clinical trials from the perspective of the estimand frameworkHans-Jochen Weber, Stephen Corson, Jiang Li, et al.
Expert Opinion on Pharmacotherapy|October 21, 2010
Efficacy and safety of ciclesonide in patients with severe asthma: a 12-week, double-blind, randomized, parallel-group study with long-term (1-year) follow-upBrian J O'Connor, Stephen Kilfeather, David Cheung, et al.
Haematologica|October 21, 2017
Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trialsRichard F Schlenk, Jürgen Krauter, Emmanuel Raffoux, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|February 26, 2026
Population PK/PD Modeling for Evaluation of Intertwining Effects of Drug and Disease on Thrombocytopenia in Acute LeukemiasTomás Sou, Kamel Malek, Hans-Jochen Weber
Statistics in Medicine|September 16, 2025
Towards Efficient Time-to-Event Dose-Escalation Guidance of Multi-Cycle Cancer TherapiesLukas A Widmer, Sebastian Weber, Yunnan Xu, et al.
Pharmaceutical Statistics|March 9, 2021
Estimands in hematologic oncology trialsSteven Sun, Hans-Jochen Weber, Emily Butler, et al.
Pharmaceutical Statistics|March 29, 2024
Time-to-event estimands and loss to follow-up in oncology in light of the estimands guidanceJonathan M Siegel, Hans-Jochen Weber, Stefan Englert, et al.
Pharmaceutical Statistics|March 27, 2023
Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questionsKaspar Rufibach, Lynda Grinsted, Jiang Li, et al.
Pulmonary Pharmacology & Therapeutics|January 15, 2009
Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthmaSøren Pedersen, Renate Engelstätter, Hans-Jochen Weber, et al.
Pharmaceutical Statistics|October 3, 2023
Duration of and time to response in oncology clinical trials from the perspective of the estimand frameworkHans-Jochen Weber, Stephen Corson, Jiang Li, et al.
Expert Opinion on Pharmacotherapy|October 21, 2010
Efficacy and safety of ciclesonide in patients with severe asthma: a 12-week, double-blind, randomized, parallel-group study with long-term (1-year) follow-upBrian J O'Connor, Stephen Kilfeather, David Cheung, et al.
Haematologica|October 21, 2017
Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trialsRichard F Schlenk, Jürgen Krauter, Emmanuel Raffoux, et al.
Pageof 1